Cargando…
Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity
The emergence and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant global morbidity, mortality, and societal disruption. A better understanding of virus-host interactions may potentiate therapeutic insights toward limiting this infection. Here we inv...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846242/ https://www.ncbi.nlm.nih.gov/pubmed/33577760 http://dx.doi.org/10.1016/j.immuni.2021.01.017 |
_version_ | 1783644700757983232 |
---|---|
author | Hoagland, Daisy A. Møller, Rasmus Uhl, Skyler A. Oishi, Kohei Frere, Justin Golynker, Ilona Horiuchi, Shu Panis, Maryline Blanco-Melo, Daniel Sachs, David Arkun, Knarik Lim, Jean K. tenOever, Benjamin R. |
author_facet | Hoagland, Daisy A. Møller, Rasmus Uhl, Skyler A. Oishi, Kohei Frere, Justin Golynker, Ilona Horiuchi, Shu Panis, Maryline Blanco-Melo, Daniel Sachs, David Arkun, Knarik Lim, Jean K. tenOever, Benjamin R. |
author_sort | Hoagland, Daisy A. |
collection | PubMed |
description | The emergence and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant global morbidity, mortality, and societal disruption. A better understanding of virus-host interactions may potentiate therapeutic insights toward limiting this infection. Here we investigated the dynamics of the systemic response to SARS-CoV-2 in hamsters by histological analysis and transcriptional profiling. Infection resulted in consistently high levels of virus in the upper and lower respiratory tracts and sporadic occurrence in other distal tissues. A longitudinal cohort revealed a wave of inflammation, including a type I interferon (IFN-I) response, that was evident in all tissues regardless of viral presence but was insufficient to prevent disease progression. Bolstering the antiviral response with intranasal administration of recombinant IFN-I reduced viral disease, prevented transmission, and lowered inflammation in vivo. This study defines the systemic host response to SARS-CoV-2 infection and supports use of intranasal IFN-I as an effective means of early treatment. |
format | Online Article Text |
id | pubmed-7846242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78462422021-02-01 Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity Hoagland, Daisy A. Møller, Rasmus Uhl, Skyler A. Oishi, Kohei Frere, Justin Golynker, Ilona Horiuchi, Shu Panis, Maryline Blanco-Melo, Daniel Sachs, David Arkun, Knarik Lim, Jean K. tenOever, Benjamin R. Immunity Article The emergence and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant global morbidity, mortality, and societal disruption. A better understanding of virus-host interactions may potentiate therapeutic insights toward limiting this infection. Here we investigated the dynamics of the systemic response to SARS-CoV-2 in hamsters by histological analysis and transcriptional profiling. Infection resulted in consistently high levels of virus in the upper and lower respiratory tracts and sporadic occurrence in other distal tissues. A longitudinal cohort revealed a wave of inflammation, including a type I interferon (IFN-I) response, that was evident in all tissues regardless of viral presence but was insufficient to prevent disease progression. Bolstering the antiviral response with intranasal administration of recombinant IFN-I reduced viral disease, prevented transmission, and lowered inflammation in vivo. This study defines the systemic host response to SARS-CoV-2 infection and supports use of intranasal IFN-I as an effective means of early treatment. Elsevier Inc. 2021-03-09 2021-01-29 /pmc/articles/PMC7846242/ /pubmed/33577760 http://dx.doi.org/10.1016/j.immuni.2021.01.017 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hoagland, Daisy A. Møller, Rasmus Uhl, Skyler A. Oishi, Kohei Frere, Justin Golynker, Ilona Horiuchi, Shu Panis, Maryline Blanco-Melo, Daniel Sachs, David Arkun, Knarik Lim, Jean K. tenOever, Benjamin R. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity |
title | Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity |
title_full | Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity |
title_fullStr | Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity |
title_full_unstemmed | Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity |
title_short | Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity |
title_sort | leveraging the antiviral type i interferon system as a first line of defense against sars-cov-2 pathogenicity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846242/ https://www.ncbi.nlm.nih.gov/pubmed/33577760 http://dx.doi.org/10.1016/j.immuni.2021.01.017 |
work_keys_str_mv | AT hoaglanddaisya leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT møllerrasmus leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT uhlskylera leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT oishikohei leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT frerejustin leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT golynkerilona leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT horiuchishu leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT panismaryline leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT blancomelodaniel leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT sachsdavid leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT arkunknarik leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT limjeank leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity AT tenoeverbenjaminr leveragingtheantiviraltypeiinterferonsystemasafirstlineofdefenseagainstsarscov2pathogenicity |